NEWS
-
2024/01/16 Correctseq
January 17-19, 2024, PST, the 5th International Conference on Base Editing, Prime Editing & Related Enzymes will be held at San Diego, California. Dr. Jia Chen, Professor of ShanghaiTech University, Co-founder of CorrectSequence Therapeutics will participate in this conference and give an oral presentation titled” Therapeutic base editing for β-thalassemia” on Jan. 17, at 5:05 - 5:20 pm, PST.
-
2024/01/08 Crectseq
The World’s First Clinical Base Editing Therapy for Hemoglobinopathy
On January 8, 2024, Shanghai, China, CorrectSequence Therapeutics Co., Ltd. (Correctseq), using innovative transformer Base Editing (tBE) technology to help people with severe diseases, announced positive results of its base editing therapy for transfusion-dependent β-thalassemia, CS-101. As a collaboration with the First Affiliated Hospital of Guangxi Medical University, the Investigator-Initiated Trial (IIT) of CS-101 has successfully cured the first treated patient with transfusion-dependent β-thalassemia, resulting in sustained transfusion-free for more than two months.
-
2023/11/24 Correctseq
CorrectSequence Therapeutics (Correctseq), a biotechnology company using innovative base editing technology to help people with severe disease, today announced that the company and the research teams from ShanghaiTech University, Wuhan University, Fudan University and Children's Hospital of Fudan University published an article entitled “Base editing of the HBG promoter induces potent fetal hemoglobin expression with no detectable off-target mutations in human HSCs” in Cell Stem Cell on November 20th, 2023, reporting a novel base editing strategy for treating β-hemoglobinopathies with transformer base editor (tBE).
-
2023/10/17 Correctseq
CorrectSequence Therapeutics to Participate in the 18th ASCAT Conference
CorrectSequence Therapeutics (Correctseq), a biotechnology company using innovative base editing technology to help people with severe disease, today announced that Dr. Susan Mou, CEO of Correctseq and Dr. Lijie Wang, head of Gene Editing Platform of Correctseq, will attend the 18th Academy for Sickle Cell and Thalassaemia Conference (ASCAT) at the County Hall London, UK on October 25-28, 2023. Dr. Lijie Wang, will give an oral presentation on Oct. 28, at 9:00 am - 11:15 am, local time.
-
2023/10/12 Correctseq
Nature Reviews Molecular Cell Biology：Base editing of organellar DNA with programmable deaminases
Recently, Prof. Jia Chen from ShanghaiTech University and Prof. Jin-Soo Kim from National University of Singapore published a review entitled Base editing of organellar DNA with programmable deaminases in Nature Reviews Molecular Cell Biology.
-
2023/10/06 Correctseq
Nature Protocols：Design and Application of the transformer Base Editor in Mammalian Cells and Mice
Prof. Jia Chen's research team and Prof. Jianfeng Li's research team at ShanghaiTech University, and Prof. Li Yang's research team at the Center for Molecular Medicine, Children’s Hospital, Fudan University jointly published a protocol paper in Nature Protocols, entitled Design and application of the transformer base editor in mammalian cells and mice. The paper describes the working principle, design scheme, and in vivo editing by the tBE.
-
2023/06/01 Correctseq
Correctseq and Thalassemia Children Celebrate the Children's Day
Today is the 73rd’s Children’s Day. On May 31, 2023, the Wuzhishan Branch of Jiusan Society, the branch of Hainan Women and Children's Medical Center and the Wuzhishan Disabled Persons' Federation co-sponsored the "Care for the Children, Walk with the Children" donation activity for exceptional children and thalassemia children to celebrate the Children’s Day, which was held in Wuzhishan Special Education School.
-
2023/01/11 PHARMCUBE Colum
As one of the most important technologies in the field of life science in the 21st century, gene editing technology is gradually showing its application potential and vigorous development. According to the data, the global genome editing market is expected to reach $4.3 billion in 2022 and $12.8 billion in 2027. The global genome editing market is expected to grow at a compound annual growth rate of 24.7% in 2022-2027.